Logo image of ALZN

ALZAMEND NEURO INC (ALZN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ALZN - US02262M6057 - Common Stock

2.24 USD
+0.1 (+4.67%)
Last: 11/26/2025, 8:15:26 PM
2.18 USD
-0.06 (-2.68%)
After Hours: 11/26/2025, 8:15:26 PM
Fundamental Rating

2

ALZN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. The financial health of ALZN is average, but there are quite some concerns on its profitability. ALZN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALZN has reported negative net income.
In the past year ALZN has reported a negative cash flow from operations.
In the past 5 years ALZN always reported negative net income.
ALZN had a negative operating cash flow in each of the past 5 years.
ALZN Yearly Net Income VS EBIT VS OCF VS FCFALZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -5M -10M

1.2 Ratios

ALZN's Return On Assets of -108.85% is on the low side compared to the rest of the industry. ALZN is outperformed by 76.92% of its industry peers.
Looking at the Return On Equity, with a value of -128.89%, ALZN is doing worse than 60.79% of the companies in the same industry.
Industry RankSector Rank
ROA -108.85%
ROE -128.89%
ROIC N/A
ROA(3y)-645.75%
ROA(5y)-439.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALZN Yearly ROA, ROE, ROICALZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALZN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALZN Yearly Profit, Operating, Gross MarginsALZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALZN has more shares outstanding
Compared to 5 years ago, ALZN has more shares outstanding
There is no outstanding debt for ALZN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALZN Yearly Shares OutstandingALZN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 200K 400K 600K
ALZN Yearly Total Debt VS Total AssetsALZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 5M 10M

2.2 Solvency

Based on the Altman-Z score of -10.90, we must say that ALZN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ALZN (-10.90) is worse than 73.92% of its industry peers.
There is no outstanding debt for ALZN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.9
ROIC/WACCN/A
WACCN/A
ALZN Yearly LT Debt VS Equity VS FCFALZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 6.03 indicates that ALZN has no problem at all paying its short term obligations.
The Current ratio of ALZN (6.03) is better than 63.79% of its industry peers.
A Quick Ratio of 6.03 indicates that ALZN has no problem at all paying its short term obligations.
ALZN has a better Quick ratio (6.03) than 65.29% of its industry peers.
Industry RankSector Rank
Current Ratio 6.03
Quick Ratio 6.03
ALZN Yearly Current Assets VS Current LiabilitesALZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 5M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.63% over the past year.
EPS 1Y (TTM)90.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.94% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y63.73%
EPS Next 2Y33.41%
EPS Next 3Y21.42%
EPS Next 5Y19.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALZN Yearly Revenue VS EstimatesALZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 100M 200M 300M
ALZN Yearly EPS VS EstimatesALZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150 -200

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALZN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALZN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALZN Price Earnings VS Forward Price EarningsALZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALZN Per share dataALZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

ALZN's earnings are expected to grow with 21.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.41%
EPS Next 3Y21.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALZN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALZAMEND NEURO INC

NASDAQ:ALZN (11/26/2025, 8:15:26 PM)

After market: 2.18 -0.06 (-2.68%)

2.24

+0.1 (+4.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-10 2025-09-10/amc
Earnings (Next)12-09 2025-12-09
Inst Owners0.09%
Inst Owner Change734.87%
Ins Owners0.81%
Ins Owner Change-0.01%
Market Cap8.51M
Revenue(TTM)N/A
Net Income(TTM)-6.89M
Analysts80
Price Target42.84 (1812.5%)
Short Float %4.61%
Short Ratio1.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)47.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.59
P/tB 1.59
EV/EBITDA N/A
EPS(TTM)-9.02
EYN/A
EPS(NY)-3.25
Fwd EYN/A
FCF(TTM)-2.13
FCFYN/A
OCF(TTM)-2.07
OCFYN/A
SpS0
BVpS1.41
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -108.85%
ROE -128.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-645.75%
ROA(5y)-439.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.03
Quick Ratio 6.03
Altman-Z -10.9
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)294.02%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.62%
EPS Next Y63.73%
EPS Next 2Y33.41%
EPS Next 3Y21.42%
EPS Next 5Y19.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.64%
OCF growth 3YN/A
OCF growth 5YN/A

ALZAMEND NEURO INC / ALZN FAQ

What is the ChartMill fundamental rating of ALZAMEND NEURO INC (ALZN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALZN.


What is the valuation status of ALZAMEND NEURO INC (ALZN) stock?

ChartMill assigns a valuation rating of 1 / 10 to ALZAMEND NEURO INC (ALZN). This can be considered as Overvalued.


Can you provide the profitability details for ALZAMEND NEURO INC?

ALZAMEND NEURO INC (ALZN) has a profitability rating of 0 / 10.


Can you provide the financial health for ALZN stock?

The financial health rating of ALZAMEND NEURO INC (ALZN) is 6 / 10.